Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Richard Bruno, Ohio State University
ClinicalTrials.gov Identifier:
NCT01787591
First received: February 6, 2013
Last updated: August 26, 2014
Last verified: August 2014

February 6, 2013
August 26, 2014
April 2013
April 2015   (final data collection date for primary outcome measure)
Plasma deuterium labeled and unlabeled alpha-tocopherol [ Time Frame: 0, 3, 6, 9, 12, 24, 36, 48, and 72 h post test meal ] [ Designated as safety issue: No ]
Plasma alpha-tocopherol concentrations will be assessed from blood samples that will be collected prior to (0 h) and at 3, 6, 9, 12, 24, 36, 48, and 72 h following each test meal.
Plasma deuterium labeled and unlabeled alpha-tocopherol and plasma and urinary labeled and unlabeled alpha-CEHC [ Time Frame: 72 h ] [ Designated as safety issue: No ]
Plasma alpha-tocopherol and alpha-CEHC concentrations will be assessed from blood samples that will be collected prior to (0 h) and at 3, 6, 9, 12, 24, 36, 48, and 72 h following each test meal and urinary alpha-CEHC concentrations will be assessed from urine collected at 8 h intervals for 24 h following each test meal.
Complete list of historical versions of study NCT01787591 on ClinicalTrials.gov Archive Site
  • Plasma alpha-CEHC [ Time Frame: 0, 3, 6, 9, 12, 24, 36, 48, and 72 h post test meal ] [ Designated as safety issue: No ]
    Alpha-CEHC concentrations will be assessed from blood samples that will be collected prior to (0 h) and at 3, 6, 9, 12, 24, 36, 48, and 72 h following each test meal.
  • Urinary alpha-CEHC [ Time Frame: 0, 8, 16, 24 h post test meal ] [ Designated as safety issue: No ]
    Alpha-CEHC concentrations will be assessed from urine samples collected prior to (0 h) and 8, 16, and 24 h following each test meal.
Plasma antioxidants and oxidative stress/inflammatory parameters [ Time Frame: 72 h ] [ Designated as safety issue: No ]
Vitamin C, carotenoids, malondialdehyde, C-reactive protein, and myeloperoxidase will be assessed from blood samples obtained prior to (0 h) administration of the test meal.
Not Provided
Not Provided
 
Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome
Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome

This study is conducted to investigate if vitamin E status in healthy individuals and individuals with metabolic syndrome can be improved by dairy fat. The investigators hypothesize that full-fat dairy will substantially increase the bioavailability of alpha-tocopherol, a form of vitamin E. The results of this study will contribute to the application of dairy fat as a simple and effective strategy for improving vitamin E status, which is partly due to poor vitamin E intake. By completing this study, the investigators anticipate developing new dietary recommendations to achieve adequate vitamin E status through the regular consumption of dairy fat paired with foods containing vitamin E.

Nonalcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome and affects >70 million Americans. Weight loss and vitamin E supplementation are leading strategies for preventing and/or treating NASH. However, the long-term success of weight loss is limited and >92% of Americans fail to meet dietary recommendations for vitamin E. Thus, the investigators' objective is to define the extent to which dairy fat facilitates adequate vitamin E status in individuals with metabolic syndrome, a population at high-risk for NASH, by improving α-tocopherol bioavailability. The investigators' central hypothesis is that full-fat dairy will substantially increase alpha-tocopherol (a-T) bioavailability to the extent needed to facilitate production of alpha-carboxyethyl-hydroxy-chromanol (a-CEHC), a metabolite of a-T that predict a-T status. The investigators will therefore complete the following specific aims: 1) define milk fat-mediated improvements in a-T bioavailability, and 2) define dairy fat-mediated improvements in a-T status. This study involves a randomized crossover study design where healthy adults and those with metabolic syndrome (n = 10/group) will ingest deuterium-labeled a-T with fat-free milk, low-fat milk, whole milk, or soy milk. Urine and blood samples will be collected at timed intervals prior to and following milk consumption. Blood collection will be performed using single needle sticks or cannula (for frequent blood collections) by skilled personnel. Plasma samples will be analyzed by liquid chromatography with mass spectrometry to determine pharmacokinetic parameters and vitamin E adequacy by measuring labeled and unlabeled a-T and a-CEHC. Risk to participants is expected to be minimal and will be outlined in the informed consent form in clear and simple terms. Upon successful completion of this study, the investigators expect to demonstrate that whole milk, compared to low-fat and fat-free milk, increases a-T bioavailability in a milk fat-dependent manner and that low-fat milk compared to soy milk (both beverages contain identical amounts of total fat, but differ in fatty acid profile), significantly improves a-T bioavailability. The investigators' results will provide timely evidence demonstrating the amount and type of fat needed to achieve optimal vitamin E status specifically in a population of significant public health concern. Overall, these studies will fill a substantial knowledge gap regarding the importance of dairy fat in contributing to optimal health and provide a simple dietary approach to ameliorate poor vitamin E status among a significant proportion of Americans.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
  • Non-alcoholic Fatty Liver
  • Metabolic Syndrome
  • Other: Fat-Free Milk
    Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
  • Other: Low-Fat Milk
    Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
  • Other: Full-Fat Milk
    Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
  • Other: Soy Milk
    Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
  • Experimental: Acute Fat-Free Milk Ingestion
    Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
    Intervention: Other: Fat-Free Milk
  • Experimental: Acute Low-Fat Milk Ingestion
    Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
    Intervention: Other: Low-Fat Milk
  • Experimental: Acute Full-Fat Milk Ingestion
    Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
    Intervention: Other: Full-Fat Milk
  • Experimental: Acute Soy Milk Ingestion
    Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
    Intervention: Other: Soy Milk
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
December 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • specific criteria of the metabolic syndrome: large waist circumference (>102 or >89 cm for men and women, respectively), high fasting triglycerides (150-300 mg/dL), low fasting HDL (<40 and <50 mg/dL for men and women, respectively), high blood pressure (>130/85 mm Hg) and high fasting glucose (110-180 mg/dL)
  • BMI: >30 kg/m2,
  • non-dietary supplement users for >2-mo
  • no use of medications known to affect lipid metabolism
  • no history of gastrointestinal disorders
  • resting blood pressure <140 mm Hg
  • not taking any medications that control hypertension

Exclusion Criteria:

  • lactose-intolerance
  • excessive alcohol consumption (>3 drinks/d)
  • >5 h/wk of aerobic activity
  • women who are pregnant, lactating, or have initiated or changed birth control in the past 3-mo
  • plasma alpha-tocopherol >20 μmol/L.
Both
18 Years to 40 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01787591
2012H0344
Yes
Richard Bruno, Ohio State University
Ohio State University
Not Provided
Principal Investigator: Richard Bruno, PhD, RD Ohio State University
Ohio State University
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP